John Jesitus
John Jesitus is a medical writer based in Westminster, CO.
Biosimilars safety performance in psoriasis
A study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
Moderate plaque psoriasis may resolve with apremilast
While there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.
Acne in pregnancy
Treating acne in pregnancy requires familiarity with FDA medication categories and having thorough discussions with patients
Dermatology journals among the 50 most cited for cosmetic procedures
The review notes a rise in first authorships among dermatologists. From 2000-2014, dermatologist first authors accounted for 8% of the most often-cited facelift articles and 5% or less of the top blepharoplasty articles. They also accounted for approximately 12% of the top brow lift articles from 2000-2009.
Recurrent cellulitis treatment can be complex
While antibiotics are a proven effective treatment for recurrent cellulitis, the effect wears off after treatment which is often done on an inpatient basis. There is little support for ongoing research in this area, researchers report.
Spironolactone prescriptions for acne rise
Between 2004 and 2013, the number of spironolactone courses per 100 females with acne rose from 2.08 to 8.13 among dermatologists and from 1.43 to 4.09 among nondermatologists, researchers report.
Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidity
Initial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
Transgender dermatology care faces unique challenges
The transgender dermatology patient may face a unique set of challenges doctors should be prepared to address, says Dr. Brian Ginsberg.
Up-and-coming fillers and neuromodulators
Injectable aesthetic products recently FDA-approved or in late stages of development include polycaprolactone, a new hyaluronic acid and multiple neuromodulators.
Medicare, coding and reimbursement challenges that lie ahead
Speaking at the American Academy of Dermatology annual meeting in February, Dr. Brett Coldiron described challenges dermatologists should be prepared for this year, including Medicare payment reductions, insurers' cost-saving strategies and practice consolidations.